Printer Friendly

Articles from M2 Pharma (December 9, 2009)

1-38 out of 38 article(s)
Title Author Type Words
Actelion to move selective S1P1 receptor agonist into advanced clinical development in psoriasis, Roche to leave S1P1 alliance. 178
Aker BioMarine, US Valensa to cooperate on health products. 161
Aldagen announces data from preclinical studies at American Society of Hematology Annual Meeting. 210
Bavarian Nordic to continue smallpox vaccine development for US Strategic National Stockpile. 155
BioAlliance Pharma announces survival data in Phase II trial of doxorubicin Transdrug. 228
BioCryst elects Charles Sanders to its board. 217
Cosmo publishes takeover offer for BioXell. 225
Cumberland, DB Pharm Korea sign agreement for commercialisation of Caldolor Injection in South Korea. 267
Dynavax's European manufacturing facility approved for commercial production of HEPLISAV. 198
FDA OKs Octapharma's replacement therapy for von Willebrand disease. 230
Finnish Oriola-KD reshuffles Nordic healthcare trade ops. 152
Galenica confirms profit growth forecast for '09. 238
Generex enters into insulin supply agreement with sanofi-aventis. 133
Genzyme appoints Robert Bertolini to board of directors. 171
Immunovaccine gets FDA nod to proceed with Phase I study of therapeutic cancer vaccine. 212
Karo Bio EUR15.8m rights issue oversubscribed. 112
LinkMed says Absorber gets patent in Europe for transplantation test. 107
Nabi to get USD5m milestone payment from GlaxoSmithKline for initiation of Phase I/II study. 248
Netcare eyes UK debut for General Healthcare. 166
Novartis Tasigna more effective than Glivec in patients with chronic myeloid leukemia. 307
Novartis to expand indications for oncology drugs, to develop life-threatening diseases pipeline. 163
Oriola-KD to separate Nordic healthcare trade business into new unit. 154
Osteologix to seek European marketing authorisation for osteoporosis drug in '11. 300
Oxagen announces completion of recruitment in Phase IIb trial in oral treatment for asthma. 260
Oxford BioTherapeutics appoints Michael Moore as chairman. 228
Oxigene announces positve preclinical data for AML drug. 197
Pfizer, Crown to develop treatments for Asian cancers. 118
Pharming interacts with US FDA for Rhucin. 126
Protalix completes NDA submission for taliglucerase alfa to FDA for treatment of Gaucher's disease. 292
QLT announces 6-month results from study of Visudyne in polypoidal choroidal vasculopathy patients. Clinical report 318
RegeneRx reports final Phase I clinical results for RGN-352. 223
Roche announces data from two pivotal studies with Herceptin in early breast cancer. 232
Roche reports positive Phase III results for MabThera/Rituxan. Clinical report 255
Sangart commences Phase IIa study of oxygen therapeutic agent MP4OX in severe trauma patients with hemorrhagic shock. 237
Sanofi Pasteur announces expansion of dengue vaccine clinical programme in Latin America. 243
Sanofi-aventis establishes strategic research alliance with California Institute of Technology. 175
SSM Health Care - St. Louis and Select Medical Corp form rehabilitation JV. 171
VaxInnate names Thomas Hofstaetter COO. 203

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters